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Abstract
Background: This study evaluated the clinical interpretations of single photon emission computed tomography (SPECT)
using a cerebral blood flow and a dopamine transporter tracer in patients with chronic mild traumatic brain injury (TBI). The
goal was to determine how these two different scan might be used and compared to each other in this patient population.
Methods and Findings: Twenty-five patients with persistent symptoms after a mild TBI underwent SPECT with both 99mTc
exametazime to measure cerebral blood flow (CBF) and 123I ioflupane to measure dopamine transporter (DAT) binding. The
scans were interpreted by two expert readers blinded to any case information and were assessed for abnormal findings in
comparison to 10 controls for each type of scan. Qualitative CBF scores for each cortical and subcortical region along with
DAT binding scores for the striatum were compared to each other across subjects and to controls. In addition, symptoms
were compared to brain scan findings. TBI patients had an average of 6 brain regions with abnormal perfusion compared to
controls who had an average of 2 abnormal regions (p,0.001). Patient with headaches had lower CBF in the right frontal
lobe, and higher CBF in the left parietal lobe compared to patients without headaches. Lower CBF in the right temporal lobe
correlated with poorer reported physical health. Higher DAT binding was associated with more depressive symptoms and
overall poorer reported mental health. There was no clear association between CBF and DAT binding in these patients.
Conclusions: Overall, both scans detected abnormalities in brain function, but appear to reflect different types of
physiological processes associated with chronic mild TBI symptoms. Both types of scans might have distinct uses in the
evaluation of chronic TBI patients depending on the clinical scenario.
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Introduction
Traumatic Brain Injury (TBI) is a major public health concern.
Although the medical community has long understood the
potential detriment of head injury [1], there has been a resurgence
of interest regarding the importance of TBI in individuals
participating in contact sports, patients with various psychological
or neurological dysfunction, and the population in general. In
addition, it has been observed that TBI survivors, even those with
mild injury, commonly face a range of clinical symptoms affecting
functional status, cognition, and mood [2]. While not everyone
with a mild brain injury has lasting symptoms, those who do often
present daunting problems regarding the differential diagnosis and
treatment [3,4]. Furthermore, since TBI can be heterogeneous in
terms of its definition, effects, and prognosis, it is often unclear how
a given TBI or multiple TBIs in the same individual will affect the
brain’s physiology and how such changes may affect clinical
symptoms [5,6]. For those individuals managing patients with a
history of TBI and persistent symptoms, knowledge of the
underlying brain physiology may ultimately be highly beneficial
for understanding the effects of the TBI and perhaps even target
future therapy. Functional neuroimaging is increasingly consid-
ered an important clinical tool in the management of TBI patients
[7–9]. This may especially be the case in patients with a history of
TBI with chronic symptoms. Importantly, functional brain
imaging may help remove some of the stigma associated with
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chronic symptoms such as headache, difficulty concentrating, or
mood changes that are otherwise difficult to evaluate [10]. If a
physiological basis for such symptoms can be established, patients
can better understand the nature of their symptoms and hopefully
be more compliant with treatment, whether it is medical,
occupational, physical, or psychological. For example, post
traumatic headache, which occurs in up to 70% of patients in
the first year and 25% after the first year [11], is frequently
debated as an entity due to a variety of factors including
medicolegal influences and a pathophysiology that is not
completely understood [12]. The possible pathophysiological
mechanism may be related to neurogenic inflammation charac-
terized by locally increased blood flow, plasma protein leakage
from blood vessels, mast cell degranulation, and platelet aggrega-
tion [13]. This inflammation can be related to the head injury
process itself or may be related to direct injury to the trigeminal
afferent nerves or to the leptomeningeal or cerebrovascular
structures that are innervated by trigeminal nerves [14]. The
inflammatory response is likely mediated by glial cells which
release a variety of cytokines that cause the release of pain
modulators from trigeminal neurons ultimately resulting in
headache.
Over the past two decades, a number of researchers, including
our group, have focused on the utility of single photon emission
computed tomography (SPECT) brain imaging to evaluate the
neurophysiology of a variety of conditions and disorders.
Depending on the tracer used, SPECT imaging can be useful
for studying cerebral blood flow (CBF), dopamine transporter
function, serotonin transporter function, as well as other processes
[15–17]. Several studies have also shown that SPECT imaging of
CBF can be helpful in TBI patients [18]. Specifically, CBF
SPECT scans can demonstrate areas of impaired brain function
which can help identify if trauma is present and which brain
system or systems are most affected. Common findings on SPECT
imaging in TBI patients include the following [9,15,19,20]:
N focal decreased CBF near the focal site of injury and/or
opposite side (contra coup)
N asymmetrical hypoperfusion in the prefrontal, temporal,
parietal or occipital lobes
N decreased CBF in the anterior temporal poles
N decreased CBF in the contralateral cerebellar perfusion.
Early studies suggested that SPECT scans may aid in
understanding a TBI patient’s symptomatology [21,22]. More
recently, some investigators have suggested that SPECT imaging
could even assist clinicians in developing treatment strategies. For
example, decreased prefrontal cortex perfusion, which can be
associated with executive dysfunction arguably may be helped with
psychostimulants [23,24] or other interventions to enhance the
function of the frontal lobes. Temporal lobe hypoperfusion has
been associated with irritability and mood instability that may be
improved with anticonvulsant or antidepressant medication.
However, studies and case reports have reported variable success
in the management of TBI patients [25,26]. Furthermore, since
different pharmacological treatments have not always demonstrat-
ed a benefit in this population, future studies are required to better
assess how well certain clinical and imaging findings can be used to
direct therapy.
SPECT may be more useful than other structural imaging
techniques such as magnetic resonance imaging (MRI) or x-ray
computed tomography (CT) in TBI patients [27]. TBI patients
often report symptoms such as headaches, memory loss, concen-
tration difficulties, perceptual sensitivities, dizziness, or emotional
liability, even when CT and/or MRI scans demonstrate no clear
abnormalities [28,29,30]. Such patients may be labeled as somatic
or malingering, especially when there are no significant neuroim-
aging abnormalities present. However, researchers investigating
the differences between functional and structural imaging tech-
niques have found SPECT to be more sensitive for detecting
abnormalities in patients with varying degrees of TBI [31]. Thus,
it is possible that patients with TBI will demonstrate functional
abnormalities on SPECT imaging that may relate to their
persistent clinical symptoms.
In addition to alterations in CBF, a growing amount of evidence
implicates damage to neurotransmitter systems, such as the
dopaminergic nervous system, in association with TBI [32]. For
example, after experimental TBI, regional increases in dopamine
levels at acute time points after acceleration–deceleration brain
injury have been observed [33]. Interestingly, cortical tissue
dopamine levels are actually depressed for up to 2 weeks post brain
injury [34]. Increases in human cerebrospinal fluid (CSF)
dopamine and its metabolites post-TBI appear to depend on both
gender and genetic variations in the dopamine transporter (DAT).
Increased dopamine metabolism may represent a compensatory
response to increased tissue dopamine levels or may be due to
additional direct effects of TBI on the regulation of the dopamine
system. The consequences of such changes might be beneficial in
that dopamine neurotransmission is restored after TBI or could
potentially be deleterious due to dopamine-induced oxidative
stress.
Another line of evidence regarding the dopaminergic effect of
TBI is that dopamine receptor agonists often benefit patients via
the promotion of central dopaminergic transmission [23,24]. This
could be a sign that dopamine release is suppressed after injury,
that dopamine uptake by the DAT is increased, or some
combination of the two. Alternatively, dopamine activity may
remain normal after injury, but this level of dopamine activity is
not adequate in the face of the injury-induced disruptions. Given
that a few studies have demonstrated beneficial effects with
dopamine antagonists, it should also be acknowledged that TBI
results in a complex series of injuries to a wide range of different
brain structures. It is important to acknowledge that any systemic
treatment for TBIwithout a well-defined window for therapy could
be both beneficial and/or detrimental to the recovery process. For
this reason, understanding the effect of TBI on dopamine
transmission is crucial for developing a proper therapeutic plan
and for promoting optimal recovery.
The current study was designed to evaluate for the first time
CBF and dopamine transporter binding in the same patient with
TBI and chronic symptoms. Two reviewers read the scans
together using a visual scoring system based upon common
clinical approaches to evaluating these scans so that this data could
be more easily utilized in current clinical practice. Scan findings
that were considered mild, moderate, or severe, could then be
provided a numerical value to assist in a more quantitative analysis
of the data. This approach was similar to previous comparison
studies performed by our group for functional neuroimaging
studies [35,36]. Thus, the overall purpose of this study was to
assess the ability of 99mTc Exametazime (CeretecTM; GE
Healthcare) SPECT to detect changes in CBF and compare those
changes to DAT binding evaluated with 123I Ioflupane (DaTs-
canTM; GE Healthcare) SPECT in the same TBI patients with
chronic symptoms. These scan findings were then compared to
clinical symptoms and neuropsychological test measures of mood,
health, and cognitive function. The goal is to help further develop
the use of SPECT imaging in TBI patients presenting with chronic
SPECT in Chronic Mild Traumatic Brain Injury
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symptoms by determining how each of these two SPECT tracers
may help clinicians better evaluate such patients.
Materials and Methods
Ethics Statements
This research was approved by the Thomas Jefferson University
Institutional Review Board. Written informed consent, approved
by the Thomas Jefferson University Institutional Review Board,
was received from all patients who participated in the study. The
clinical Investigation was conducted according to the principles
expressed in the Declaration of Helsinki.
Subjects Selection
Twenty-five patients (14M/11F; mean age 51616) with one or
more prior traumatic brain injuries with chronic symptoms (see
demographics in Table 1) were recruited. Subjects were recruited
primarily from the Neurology Department at Thomas Jefferson
University and also from the Concussion Clinic at Magee
Rehabilitation Hospital both in Philadelphia. All subjects were
evaluated with both 99mTc Exametazime and 123I Ioflupane
SPECT. The scans from these subjects were also compared to 10
99mTc Exametazime SPECT scans from control subjects with no
history of head injury (5M/5F; mean age 5466) and 10 123I
Ioflupane SPECT scans from another group of control subjects
also with no history of head injury (5M/5F; mean age 57614). 123I
Ioflupane SPECT scans were obtained for the age and gender
matched healthy control subjects from the Parkinson Progression
Marker Initiative database (www.ppmi-info.org) and subjected to
the identical analysis. All TBI patients had a history of at least one
prior head injury over 6 months prior to the scan with continued
symptoms that included memory loss or other cognitive problems
(N= 20), headaches (N=9), emotional problems such as anxiety or
depression symptoms (N= 11), or other symptoms (see Table 1 for
patient demographics and TBI history). Most subjects were
currently employed or were students such that their TBI
symptoms did not limit their capacity to function. Subjects did
not have other neurological disorders or meet criteria for chronic
traumatic encephalitis.
All subjects were evaluated with several neuropsychological
questionnaires to assess health and emotional status including the
Profile of Mood Scale (POMS) which measures six identifiable
mood or affective states: Tension-Anxiety, Depression-Dejection,
Anger-Hostility, Fatigue-Inertia, and Confusion-Bewilderment
[37], the Spielberger State-Trait Anxiety Inventory (STAI) to
measure anxiety [38], the Beck Depression Inventory (BDI) to
measure depressive symptoms [39], and the Short Form-12 (SF-
12) for general health [40] which is also subsequently divided into
the Physical Component Score (PCS) and Mental Component
Score (MCS).
SPECT Acquisition
All scans were performed at the Thomas Jefferson University
Department of Nuclear Medicine according to their standard
clinical protocols. Approximately 10 minutes prior to injection, an
intravenous cannula (IV) was placed in one arm. For CBF scans,
each subject was injected with their eyes open and ears unoccluded
in a dimly lit room with limited ambient environmental stimuli.
Subjects received the recommended 99mTc Exametazime dosage
in the package insert of 370–740 MBq (10–20 mCi) intravenously.
Imaging was performed on a Philips Forte dual headed SPECT
scanner with ultrahigh resolution low energy collimators approx-
imately 30 minutes after injection and acquired over 30 minutes.
Images were reconstructed in the axial, sagittal, and coronal
planes using filtered back projection and Chang’s attenuation
correction. Within one month of the CBF SPECT scan, subjects
underwent dopamine transporter SPECT imaging. For this scan,
patients received 16 drops of Lugol’s solution for thyroid blocking
approximately 30 minutes prior to injection. Ten minutes prior to
injection, an IV canula was placed in one arm. Each subject
received 111 to 185 MBq (3 to 5 mCi) of 123I Ioflupane
intravenously as per the package insert. They underwent scanning
approximately 3 hours after injection for 45 minutes.
Image Interpretation
All SPECT scans were interpreted by two board certified
nuclear medicine physicians with extensive experience interpreting
brain SPECT scans. The reviewers interpreted all the scans
together by consensus in a randomized order for both the CBF
and DAT SPECT scans. The reviewers were blinded to any
clinical information. For the CBF scans, the assessment was
performed to qualitatively rate the cerebral blood flow in the four
major cortical brain regions – the frontal, temporal, parietal, and
occipital lobes, as well as the anterior and posterior cingulate,
caudate, basal ganglia, thalamus and cerebellum. With the left and
right hemispheres included, there was a total of 18 brain regions
evaluated. Each structure was rated for CBF in both the left and
right hemisphere. We used a previously described approach for
interpreting functional imaging scans [35,36] such that the CBF of
each anatomic structure on the SPECT scan was given a score:
4 = normal activity; 3 =mildly decreased activity; 2 =moderately
decreased, 1= severely decreased; and 0= no activity. DAT
SPECT images were assessed visually using a similar semiquan-
titative score ranging from 4=normal binding; 3 =mildly
decreased binding; 2 =moderately decreased binding, 1= severely
decreased binding; and 0= no binding. Four regions were
evaluated, the left and right caudate, and the left and right
putamen.
Data Analysis
Initially, descriptive statistics were used regarding the number
and extent of abnormal activity on the CBF and DAT binding
scans from the TBI patients and controls. A linear regression
model was used to compare the neuropsychological test scores to
CBF scores in relevant regions for the entire cohort of TBI
patients. For DAT binding scans, since there was a limited
dynamic range of values given only 4 relevant brain regions, a t-
test was used to compare those patients with highest and lowest
quartiles of the neuropsychological test scores to the overall striatal
DAT binding. Significant findings were cross validated with non-
parametric tests (Wilcoxon Two Sample Test for comparison of
groups and Spearman rank analysis for correlations) to account for
possible skewness of the data. Finally, the activity for the CBF
scans and DAT binding were compared to each other particularly
in the basal ganglia, but also between the frontal regions on CBF
scans and the basal ganglia on the DAT scans. Where indicated,
correction for multiple comparisons was made using the False
Discovery Rate method [41].
Results
Patients with a history of TBI and persistent symptoms generally
had one or more abnormal perfusion findings on their brain scans
(see Figures 1 and 2). In fact, TBI patients had an average of 6
brain regions with abnormal perfusion compared to controls who
had an average of 2 abnormal regions out of 18 regions evaluated
(see Table 2). In controls, all decreases in perfusion were mild
whereas in the TBI group, 10 of 25 patients had regions graded as
SPECT in Chronic Mild Traumatic Brain Injury
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moderate or severely decreased. Given the sample size, a
sensitivity and specificity between the groups could not be
performed, however, the number of abnormal regions was
significantly higher in the TBI group compared to the control
group (p,0.001). On the 123I Ioflupane SPECT, 72% of TBI
patients had abnormal DAT binding compared to 20% of controls
(p = 0.01). However, the findings in the controls were typically
mild and restricted to a single putamen, which may have even
been related to artifact, whereas the TBI patients were more likely
to have involvement of the caudate or both putamen. Interestingly,
the TBI patients in this cohort had the abnormalities more in the
left striatum with significantly lower (by Wilcoxon Two Sample
Test) binding in the left caudate and left putamen compared to
controls (left caudate mean of 3.660.6 in TBI and 4.060.0 in
controls, p = 0.02; left putamen mean of 3.360.7 in TBI and
3.860.3 in controls, p = 0.01).
When CBF was compared to DAT binding, there were no clear
associations between findings. Abnormal CBF in the caudate or
basal ganglia did not appear to predict or correspond to abnormal
DAT binding. Even asymmetries were not comparable with 10
patients having asymmetric CBF and 11 patients having asym-
metric DAT binding, but concordance in only 2 patients.
We performed a limited set of comparisons between clinical
symptoms, neuropsychological test scores, and CBF or DAT
binding based upon expected associations observed in prior
Table 1. Demographic and clinical information for TBI patients.
Subject # Gender
AGE
(at study)
Total Number
of TBIs Cause of TBI Concurrent CNS Conditions
1 M 76 1 Sports Memory loss, migraine headaches,
2 M 61 2 Sports Memory loss, attention problems, anxiety, depression
3 M 27 3 Blast Memory loss, attention deficits, anxiety, depression
4 F 56 2 Sports Memory loss, headaches
5 F 69 1 Sports Depression
6 F 27 2 Sports Headaches
7 M 64 4 MVA Depression, anxiety
8 M 18 1 Sports Loss of concentration, apathy
9 F 34 1 Sports Severe vertigo, memory loss, attention/concentration problems
10 M 58 4 Sports Memory loss, headaches
11 F 61 3 MVA Headaches, dizziness, memory loss, sleep disturbances
12 F 50 1 MVA Memory loss, attention/visual problems
13 M 58 1 Accident Vertigo, sleep problems, memory loss
14 M 36 1 Accident Memory loss, attention deficits
15 F 39 5 Accident Memory loss, attention deficits, language problems, anxiety, depression
16 F 25 3 Sports Memory loss, attention deficits, depression, anxiety, apathy
17 F 65 2 Memory loss, anxiety
18 M 68 1 MVA Memory loss, tremors, agitation, disinhibition
19 M 61 8 MVA Headaches, memory loss, language problems, attention deficits
20 M 62 2 MVA Severe headaches, depression
21 F 58 1 MVA Visual problems, headaches, tinnitus, memory loss
22 F 70 3 MVA Memory loss, anxiety
23 M 46 1 MVA Memory loss, attention deficits, depression
24 M 42 3 MVA Memory loss, balance problems, falls
25 M 52 1 MVA Visual problems, memory loss, headaches, vestibular problems
MVA=motor vehicle accident; Accident = other type of accidental trauma.
doi:10.1371/journal.pone.0087009.t001
Figure 1. 99mTc Exametazime and 123I Ioflupane SPECT studies
in a 61 year old male subject with multiple prior TBIs
presenting with headache and memory loss. Note the markedly
decreased CBF primarily in the frontal lobes bilaterally (yellow arrows).
However, this same patient had robust DAT binding in the striatum
(blue arrows) with no significant abnormalities.
doi:10.1371/journal.pone.0087009.g001
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studies. There were some interesting findings in the current
cohort. For patients reporting headaches, there were significant
findings compared to those patients without headaches. Patients
with headaches had lower right frontal (3.860.4 without vs.
3.160.7 with headaches, p = 0.02) and increased left parietal CBF
(3.460.6 without vs. 4.060.0 with headaches, p = 0.03 by
Wilcoxon Two Sample Test). Please note that the findings for
the right frontal lobe and left parietal lobe survived correction for
multiple comparisons. Interestingly, there was no clear association
between those reporting cognitive impairment or the type of
impairment (i.e. loss of concentration, loss of memory, etc.) and
either CBF or DAT binding. However, this lack of a finding might
be due in part to so many patients reporting symptoms (only 3
patients reported no cognitive symptoms).
With regard to specific neuropsychological measures, there were
also several interesting findings related to CBF and DAT binding.
For the SF-12 PCS, there was a significant correlation between
low CBF in the left frontal lobe and reports of lower physical
health (r = 0.50, p= 0.01 corrected). Similarly, there was a
significant correlation (Spearman rank correlation) between low
CBF in the right temporal lobe and reports of lower physical
health (r = 0.54, p= 0.005 corrected). The implication is that those
patients with worse perceived physical health have lower CBF in
these regions. Total CBF score for all regions correlated negatively
with fatigue (r = 0.44, p= 0.03) but did not correlate with any
other measures on the POMS. Furthermore, there were no
significant findings between the MCS and CBF values.
For DAT binding, those patients in the lowest quartile for
depression compared to the highest quartile had significantly
higher binding in the total striatum (3.360.7 and 3.760.2
respectively, p = 0.01 by Wilcoxon Two Sample Test). This is
consistent with our prior depression data which demonstrated
increased DAT binding in patients with depression and also in
controls with depressive symptoms [42,43]. For the SF-12 MCS,
the results for those with scores in the lowest quartile versus the
highest quartile showed DAT binding of 3.860.2 and 3.360.6
respectively (p = 0.02 by Wilcoxon Two Sample Test). Finally,
there was higher DAT binding in patients with the highest quartile
scores on the Spielberger trait anxiety scale versus those who were
in the lowest quartile (3.860.1 versus 3.260.7, p= 0.02 by
Wilcoxon Two Sample Test).
Discussion
The overall purpose of this study was to compare CBF using
99mTc Exametazime SPECT and DAT binding using 123I
Ioflupane SPECT in patients with persistent symptoms associated
with a history of mild TBI. As described below, several studies
have evaluated CBF or DAT binding alone in similar cohorts of
patients, but not together [44,45,46]. For example, prior research
studies have explored the relationship between CBF findings on
SPECT imaging and TBI both in terms of diagnosis and clinical
symptoms.
Some early studies compared the value of CBF SPECT imaging
to anatomical findings on MRI or CT in TBI patients. Ichise et al.
[19] studied 29 patients with chronic symptoms after either mild or
major head injury. SPECT imaging detected abnormalities in
66% patients whereas MRI detected abnormalities in 45% and
CT in 34% of patients. The SPECT scans also correlated better
with tests of memory, attention and executive function than did
structural imaging. A study of 43 patients with persistent post-
concussive symptoms demonstrated abnormal SPECT scans in
53% of patients while MRI was read as abnormal in 9% and CT
scan in only 5% of patients [44]. Although the SPECT scan results
appeared to be more sensitive in detecting cerebral abnormalities
in these patients, current neuropsychiatric symptoms did not seem
to correlate with the SPECT scan findings. A more recent study of
patients with acute mild TBI demonstrated CT abnormalities in
34% of patients while SPECT showed abnormal CBF in 63%
corroborating earlier findings [45]. As in our study, the most
common abnormality on many of these previous studies was
hypoperfusion in the frontal lobes. We also found on average 6
regional abnormalities in CBF in the TBI group suggesting a more
widespread pathophysiological process similar to other studies
[20].
In the current study, we found a number of correlations
between CBF and various clinical or neuropsychological param-
eters. For example, patients reporting headaches as part of their
post-TBI symptoms had significant differences in the CBF in their
right frontal lobe, and left parietal lobe. Such findings, which may
reflect diffuse axonal injury and inflammation, are also consistent
with several other studies of headache and pain syndromes
[47,48,49]. An early study reported decreased cerebral blood flow
is associated with common migraines suggesting that migraine
attacks occur in connection with exacerbations of preexisting
changes of neuronal activities, cerebral perfusion and metabolism
[50]. In addition, in our study, low CBF in the left frontal lobe and
right temporal lobe correlated with poorer reported physical
health. The finding of decreased left frontal CBF is consistent with
the well-known association of left dorsolateral prefrontal cortical
dysfunction and depressed mood. Just as ischemic stroke,
arteriovenous malformations, and neoplastic mass lesions in this
area are often associated with depressed mood, this study suggests
that TBI induces a ‘functional lesion’ of this area altering self-
perception of health in a manner consistent with depressive
thinking (anhedonia and despair) [51,52,53].
Other studies have evaluated the correlation between SPECT
CBF findings and clinical findings as well as prognosis. For
example, one study evaluated the results of neuropsychological
tests in 12 alert, responsive patients aged 18–26 years, who were
2–13 months after head injury and found that global CBF was
significantly decreased in patients with head injury relative to age-
Figure 2. 99mTc Exametazime and 123I Ioflupane SPECT studies
in a 58 year old male subject with a history of a single TBI with
clinically presenting with problems with memory, sleep, and
vertigo and no clear parkinsonian features. The CBF shows only a
mild decrease in the right temporo-parietal region. However, DAT
binding is markedly abnormal with preserved uptake primarily in the
caudate (R.L) and minimal uptake in the putamen bilaterally.
doi:10.1371/journal.pone.0087009.g002
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matched controls [54]. In that study, 3 of 4 patients with a well-
localized injury had focally decreased CBF over the affected
region. Also in that cohort, 2 of 3 patients with diffuse injury who
underwent repeat studies 5–14 weeks after their initial study had
improvement on both their psychological tests and CBF. These
results suggested that the chronic sequelae of head injury include
decreased CBF, presumably reflecting decreased cerebral metab-
olism related to diffuse axonal injury or continued inflammatory
response, which correlates with the neuropsychological impair-
ment. Our current study supports this overall hypothesis given the
generally reduced CBF in patients with chronic symptoms related
to prior TBI.
A more thorough evaluation of the correlation between SPECT
findings and prognosis was found in a study by Jacobs et al. which
prospectively evaluated 67 mild-to-moderate brain injured patients
[55]. Each patient had a clinical evaluation and SPECT scan
Table 2. General evaluation results of the 99mTc Exametazime and 123I Ioflupane SPECT scans (note that several additional
regions were evaluated but not listed).
99mTc Exametazime Results 123I Ioflupane SPECT Results
TBI
Subject R Front L Front R Par L Par R Temp L Temp R Striat L Striat R Thal L Thal R Caud L Caud R Put L Put
1 ABN ABN N N N N N ABN ABN ABN N ABN ABN ABN
2 N N ABN N N N N ABN N N N N N ABN
3 N N ABN N N ABN N ABN N N N N N N
4 N ABN N N N ABN N ABN N ABN ABN N ABN N
5 N ABN N ABN N ABN ABN ABN N ABN N N N N
6 ABN ABN N N N ABN N ABN N ABN N N N ABN
7 ABN ABN N N N N N ABN N ABN N ABN N ABN
8 ABN N N ABN N ABN N ABN N N N ABN N ABN
9 ABN ABN ABN N ABN N ABN ABN N N N N N N
10 N N ABN N ABN N N N ABN N N ABN N N
11 ABN N ABN N N N N ABN N ABN N N N ABN
12 N ABN N N ABN N ABN N N N N ABN N ABN
13 N N ABN ABN ABN N N N N N ABN N ABN ABN
14 ABN N ABN N N N ABN N N N N N ABN N
15 N ABN N ABN N ABN N ABN N ABN N N ABN ABN
16 N ABN ABN N ABN N N ABN N ABN N ABN N ABN
17 N ABN N N N ABN N N N N ABN N ABN N
18 N ABN N ABN N ABN ABN N N N N N N N
19 ABN ABN N N ABN ABN N N ABN ABN N ABN N ABN
20 ABN ABN N N ABN ABN N ABN N ABN N N N N
21 ABN ABN N N ABN ABN ABN ABN ABN ABN N ABN N ABN
22 N N N N N N N N ABN ABN N N N N
23 N ABN N ABN ABN ABN N ABN N N N N N ABN
24 N ABN N ABN N N ABN ABN N ABN N N N N
25 ABN ABN N N N N ABN ABN ABN ABN N ABN N ABN
Control
1 ABN N N N N N N N N N N N ABN N
2 N ABN N N N N ABN ABN N N N N N N
3 ABN ABN ABN ABN N N N N N N N N N N
4 N N N N N N ABN N ABN N N N N N
5 N N N N N ABN N N N N N N N N
6 N N N N N N N N N N N N N N
7 N N N N N N N ABN N ABN N N ABN N
8 N ABN N N N N N N N N N N N N
9 N N ABN ABN N ABN N N N N N N N N
10 N ABN N N N ABN N N N N N N N N
N=Normal; ABN= abnormal; R Front = Right Frontal; L Front = Left Frontal; R Par = Right Parietal; L Par = Left Parietal; R Temp=Right Temporal; L Temp= Left Temporal;
R Striat = Right Striatum; L Striat = Left Striatum; R Thal = Right Thalamus; L Thal = Left Thalamus; R Caud = Right Caudate; L Caud = Left Caudate; R Put = Right Putamen; L
Put = Left Putamen.
doi:10.1371/journal.pone.0087009.t002
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within four weeks of the initial injury and three months after the
first scan. This study reported that of the 33 patients who showed
no significant abnormalities on their initial SPECT scan, 97%
experienced resolution in their clinical symptoms within three
months. However, of the 34 patients with abnormalities on their
initial SPECT scans, 59% continued to experience significant
clinical symptoms three months later. The authors reported a
positive predictive value of an abnormal initial scan of only 59%,
but if the 12 month follow up scan was also abnormal, the
sensitivity for the repeat SPECT was 95%. These authors
suggested that negative initial SPECT studies are a reliable
predictor of a favorable clinical outcome. The results showed that
SPECT alterations correlated well with the severity of the trauma
and a negative initial SPECT study was a reliable predictor of a
favorable clinical outcome. The authors suggested that in cases
with a positive initial SPECT scan, a follow-up consisting of a
combination of SPECT and clinical evaluation is necessary
especially in patients suffering from post-conclusive symptoms.
Our current study would corroborate the notion that positive
SPECT scans are associated with chronic symptoms in TBI
patients.
Another prospective study evaluated 136 patients with mild
head injury who underwent initial SPECT imaging within 4 weeks
after the trauma and again up to 12 months post injury [56]. That
study revealed that clinical normalization occurred earlier than
normalization of CBF. However, at 12 months post injury, the
investigators observed considerable improvement in the specificity
and positive predictive value of SPECT (85% and 83%,
respectively). Furthermore, persistent lesions on the SPECT scan
were correlated with severity and to localization in the frontal
cortex. The authors suggested that a normal 99mTc-HMPAO
SPECT scan early in the post TBI course may be a reliable tool for
predicting improvement. As with our study, patients with
persistent symptoms frequently have a variety of CBF abnormal-
ities even a year or more after TBI.
A study by Bonne et al. [57] studied 28 clinically symptomatic
male subjects with mild TBI and twenty matched controls with
neuropsychological testing and brain SPECT imaging. Similar to
our study, mild TBI patients demonstrated regions of hypoperfu-
sion in the frontal lobes, temporal lobes, and sub-cortical
structures which was generally concordant with neuropsycholog-
ical localization. The results from these CBF SPECT studies, in
addition to the results from the current study support using
SPECT to help assess the diagnosis, prognosis, and treatment of
TBI patients.
In addition to alterations in CBF, a growing amount of evidence
implicates damage to the dopaminergic nervous system in
association with TBI. Additional evidence of dopamine system
dysfunction after TBI is based upon data showing altered DAT
binding after TBI. One study of only 10 subjects used single
photon emission computed tomography (SPECT) with beta-CIT
to show that striatal DAT binding was decreased in patients up to
4–5 months after severe TBI, even in cases where there was no
evidence of structural striatal injury [46]. Patients with TBI also
had significantly lower D2 post-synaptic receptor binding as
measured by IBZM SPECT. However, the DAT deficit was more
marked than the D2 receptor loss. The findings suggested that
nigrostriatal dysfunction could be detected using SPECT following
TBI despite relative structural preservation of the striatum.
However, there still have been no studies that explored the
comparison between dopamine function and cerebral blood flow
as measured by SPECT.
The current study provides unique data by being able to directly
compare CBF and DAT binding in the same TBI patients. Our
SPECT results show that both CBF and DAT binding are
abnormal in TBI patients with chronic symptoms. Furthermore,
both CBF and DAT abnormalities appear to correlate with clinical
symptoms. However, there does not seem to be a good correlation
between CBF and DAT SPECT scan findings.
There are several limitations with regard to interpreting the
findings in this study. One limitation is that the SPECT scans were
all interpreted together by two expert reviewers. Thus, this study
does not provide information on inter-rater or intra-rater
reliability for the scans. However, the purpose of this study was
to determine how these scans might be utilized in the traditional
clinical setting in TBI patients so we sought to interpret the scans
under optimal conditions. Given the potential importance of
utilizing these scans for the clinical evaluation of chronic TBI
patients suggested by the current data, future studies with larger
numbers of subjects will be needed to better assess how well these
scans can be evaluated by different readers under more complex
conditions. However, such a study can potentially yield data to
support the broader use of SPECT imaging in this population. In
addition, it will be important to perform additional quantitative
analyses in the future. Again though, since quantitative analysis
with tools such as region of interest analysis or statistical
parametric mapping is not typically used in the clinical setting,
they were not performed as part of the current study. Another
limitation for SPECT’s use in TBI is that typically no pre-trauma
SPECT study is available for comparison. Thus, it is often not
possible to determine the date of trauma with functional
neuroimaging. Even remote trauma from childhood can present
with neuroimaging findings similar to those seen in more recent
trauma.
Conclusion
Overall, this study provides the first data on CBF and DAT
binding in the same patients with a history of TBI and chronic
symptoms. The results demonstrate that such TBI patients
frequently have a number of perfusion and DAT binding
abnormalities. Such abnormalities appear to correlate with specific
symptoms or clinical measures. But, interestingly, the scans do not
appear to correlate well with each other. The implication of this
last finding is that the scans appear to provide insight into two
separate pathophysiological processes associated with TBI symp-
toms. Thus, both scans might ultimately have utility in the setting
of patients with TBI and persistent symptoms.
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